Архитектура Аудит Военная наука Иностранные языки Медицина Металлургия Метрология
Образование Политология Производство Психология Стандартизация Технологии


DOSAGE AND ADMINISTRATION



COMPOSITION

a) Each enteric coated tablet contains Diclofenac Sodium 25 mg.

b) Each enteric coated tablet contains Diclofenac Sodium 50 mg.

c) Each enteric coated tablet contains Diclofenac Sodium 100 mg.

d) DIC INJECTION Each ml of injection contains Diclofenac Sodium 25 mg.

DESCRIPTION

DIC (Diclofenac) is a potent non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It also has some uricosuric effect. Diclofenac inhibits cyclo-oxygenase activity with a reduction in the tissue production of prostaglandins such as PgF2 and PgE2.The anti-inflammatory effect, measured in the adjuvant induced arthritis model is greater than that of aspirin and similar to indomethacin.

INDICATIONS

- Rheumatoid arthritis.

- Osteoarthritis.

- Low back pain and other acute musculoskeletal disorders such as tendonitis, tenosynovitis, bursitis, sprains, strains and dislocations.

- Ankylosing spondylitis.

- Acute gout.

- Control of pain and inflammation in orthopaedic, dental other minor surgery.

- Juvenile chronic arthritis.

- Postoperative pain.

- Pain of renal colic.

CONTRAINDICATIONS

Active or suspected peptic ulcer or gastrointestinal bleeding.

Previous sensitivity to diclofenac sodium.

Asthmatic patients in whom attacs of asthma, urticarial or acute rhinitis are precipitated by aspirin or other NSAID`s possessing prostaglandin synthetase inhibiting activity.

DOSAGE AND ADMINISTRATION

a) Oral. For symptomatic relief of rheumatoid arthritis, the usual daily dosage is 150 to 200 mg given in two to four divided doses.

For osteoarthritis, 100 to 150 mg is given daily in two or three divided doses.

For ankylosing spondylitis, 100 to 125 mg is given daily in four or five divided doses.

b) Parenteral. 75 mg i. m. 1-2 times daily by deep intragluteal injection for 2-3 days.

PRECAUTIONS

DIC (Diclofenac) may be used cautiously in patients with history of dyspepsia, or other g.i. disorders, blood coagulation disorders, severe hepatic or renal disease. Perform blood counts during long-term therapy. Sately in pregnancy lactation and children has not been established.

PRESENTATION

DIC tablets of 25 mg, 50 mg and 100 mg are available in pack of 10’s and in bulk pack of 1000’s.

DIC injection is available in clear glass ampoules of 3 ml.

 

 

DAFLON

Contents
Micronized, purified flavonoid fraction (diosmin 450 mg, hesperidin 50 mg).


Description

Each film-coated tablet contains micronized purified flavonoid fraction 500 mg (diosmin 450 mg and flavonoids expressed as hesperidin 50 mg).

Mechanism of Action

Daflon exerts an action on the vasculary return system. At the venous level, it reduces venous distensibility and reduces venous stasis. At the microcirculatory level, it normalises capillary permeability and reinforces capillary resistance.

Indications

Treatment of symptoms related to venolymphatic insufficiency (heavy legs, pain). Treatment of functional symptoms related to acute hemorrhoidal attack.

Dosage and administration

Usual Dose: 2 tablets daily in 2 divided doses, mid-day and evening at meal times.

Acute Hemorrhoidal Attack: 6 tablets daily for the first 4 days, then 4 tablets daily for 3 days.

Contraindications

Hypersensitivity to any of the components of Daflon 500 mg.

Special Precautions

Hemorrhoidal Attack: The administration of Daflon 500 mg does not preclude treatment for other anal conditions.

The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

Impairment of Fertility: Reproductive toxicity studies showed no effect on fertility in male and female rats.

Adverse Reactions

Summary of Safety Profile: Adverse Reactions reported with Daflon 500 mg in clinical trials are of mild

intensity. They consist mainly in gastrointestinal events (GI) (diarrhoea, dyspepsia, nausea, vomiting).

 

List of Adverse Reactions:

Interactions

Incompatibilities: None.

Storage

Store below 30°C.

Shelf-Life: 3 years.

Presentation / Packing

Film-coated tab 500 mg x 30’s

 

INDOMETHACIN

Composition

Indomethacinum 10 g in ointment base up to 100 g.

Properties

The ointment exhibits anti-inflammatory and antiexudative properties. Being a prostaglandin synthesis inhibitor it exercises both keratolytic and antiseptic effect. The excellent resorption of this ointment ensures its therapeutic effect creating high tissue concentrations at the application areas.

Indications

Acute and chronic rheumatic polyarthritis, osteoarthrosis, Behterev's disease, degenerative articular diseases, discopathies, neuritis, plexitis, radiculitis, post-operative oedema, contusions, thrombophlebitis, hyperkeratolytic eczemas, herpes zoster, arthropathic psoriasis, climacteric keratosis etc.

Dosage and administration

Rub the affected joints or skin areas a few-centimetre-long tube squeeze of Indomethacin ointment, 2-3 times a day. Total daily amount should not exceed 15 cm for adults and 7.5 cm for children.

Contraindications

Drug allergy, peptic and duodenal ulcer, bronchial asthma, epilepsy, Parkinsonism, during pregnancy and breast feeding, leucopenia, haemorrhagic diathesis (thrombocytopenia and coagulopathy).

Side-effects

Allergic reactions, thrombocytopenia, agranulocytosis. Following long-term treatment, however rarely, headache, drowsiness, depressive states, hepatitis and pancreatitis can be observed especially in more susceptible patients.

Drug interactions

Therapeutic effect of Indomethacin decreases, if applied concurrently with salycilates. Probenecid suppresses renal excretion of indomethacin. The effect of Indomethacin is enhanced if applied in combination with glucocorticoids and pyrazolon derivatives.

Precautions

If treatment lasts longer than ten days, follow carefully the patient’s blood picture (leucocytes, thrombocytes). If applied in combination with antibiotics, anticoagulants or antidiabetic drugs ensure control of proper clinical and laboratory parameters.

Package

Ointment in aluminium tubes of 40 g.

Storage

At moderate temperature (15-30°C) in light-protected areas.

Shelf life

2 years.

Produced by

TROYAPHARM Co

 

DROTAVERINE

Composition

Drotaverine 40mg

Description:

Myotropic antispasmodic, a derivative of isoquinoline. Inhibits phosphodiesterase (PDE) IV, which leads to the accumulation of intracellular cyclic adenosine monophosphate (cAMP) and hence in inactivation of the myosin light chain kinase, resulting in smooth muscle relaxation. It has direct effect on smooth muscle can be used as an antispasmodic when contraindicated drugs from the group m-anticholinergics (angle-closure glaucoma, prostatic hyperplasia).

Indications

Smooth muscle spasm urinary and biliary organs (kidney colic, pyelitis, tenesmus, biliary colic, intestinal colic, biliary dyskinesia and gallbladder hyperkinetic type, cholecystitis, postcholecystectomical syndrome).

‒ Spasm of smooth muscles of the gastrointestinal tract (usually as part of combination therapy): pilorospazm, gastro, gastric ulcer and duodenal ulcers, spastic constipation, spastic colitis, proctitis.

‒ Tensor headache.

‒ Dysmenorrhea, threatening miscarriage, threatening preterm delivery, postpartum contractions.

Contraindications

Hypersensitivity to the drug, pronounced hepatic and renal insufficiency, severe heart failure (low cardiac output syndrome), lactation.

This dosage form is not used in children younger than 3 years.

Due to the presence of the drug lactose monohydrate (milk sugar), its reception is contraindicated in congenital lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Precautions

Drotaverine should be used with caution in patients with arterial hypotension, atherosclerosis of the coronary arteries, prostatic hyperplasia, angle-closure glaucoma, pregnancy.

Dosage and Administration

Adults: 40-80 mg (1-2 tablets) 2-3 times a day. The maximum daily dose - 240 mg.

Children aged 3 to 6 years of age - a single dose of 20 mg, the maximum daily dose - 120 mg (2-3 hours); aged 6 to 12 years of single - 40 mg, the maximum daily dose - 200 mg; multiplicity of application - 2-5 times a day.

Side effect

Dizziness, headache, insomnia, palpitations, blood pressure, allergic reactions, nausea, constipation, sensation of heat, sweating

Storage conditions

In a dry, dark place at a temperature no higher than 25°C.

Keep out of the reach of children.

Shelf life

3 years.

Composition

Each tablet contains 500mg Paracetamol PhEur.

Indications

For the relief of mild to moderate pain and febrile conditions, e.g. headache, toothache, colds, influenza, rheumatic pain and dysmenorrhoea.

Dosage and administration

For oral administration.

Adults including the elderly and children over 16 years: One to two tablets every 4-6 hours as required, to a maximum of 8 tablets daily in divided doses.

Children 10-15 years: One tablet every 4-6 hours as necessary to a maximum of 4 doses in 24 hours.

Children under 10 years: Not recommended for children under 10 years of age. Alternative presentations of paracetamol are recommended for paediatric usage in order to obtain suitable doses of less than 500mg.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Interaction

• Anticoagulants - the effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding. Occasional doses have no significant effect.

• Metoclopramide – may increase speed of absorption of paracetamol.

• Domperidone – may increase speed of absorption of paracetamol.

• Colestyramine – may reduce absorption if given within one hour of paracetamol.

• Imatinib - restriction or avoidance of concomitant regular paracetamol use should be taken with imatinib.

Undesirable effects

Adverse effects of Paracetamol are rare but hypersensitivity including skin rash may occur.

There have been reports of blood dyscrasias including thrombocytopenia, neutropenia, pancytopenia, leukopenia and agranulocytosis but these were not necessarily causality related to Paracetamol.

Overdose

Liver damage is possible in adults who have taken 10g or more of Paracetamol.

Shelf life

3 years

Storage

Store below 25°C in a dry place. Protect from light.

AMOXIL® (amoxicillin)

Capsules: 250 mg, 500 mg

Tablets: 500 mg, 875 mg

Powder for Oral Suspension: 125 mg/5 ml, 200 mg/5 ml, 250 mg/5ml, 400 mg/5 ml (3)

INDICATIONS

AMOXIL is a penicillin-class antibacterial indicated for treatment of infections due to susceptible strains of designated microorganisms.

Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract.

In combination for treatment of H. pylori infection and duodenal ulcer disease.

DOSAGE AND ADMINISTRATION

In adults, 750-1750 mg/day in divided doses every 8-12 hours.

In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours.

Treatment of gonorrhea is 3 grams as a single oral dose.

The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours.

Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and

30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.

CONTRAINDICATIONS

History of a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to AMOXIL or to other beta-lactams (e.g. penicillins or cephalosporins)

WARNINGS AND PRECAUTIONS

Anaphylactic reactions: Serious and occasionally fatal anaphylactic reactions have been reported in patients on penicillin therapy. Serious anaphylactic reactions require immediate emergency treatment with supportive measures.

Clostridium difficile-associated diarrhea (ranging from mild diarrhea to fatal colitis): Evaluate if diarrhea occurs.

ADVERSE REACTIONS

The most common adverse reactions (>1%) observed in clinical trials of AMOXIL capsules, tablets or oral suspension were diarrhea, rash, vomiting, and nausea.

DRUG INTERACTIONS

Probenicid decreases renal tubular secretion of amoxicillin, which may result in increased blood levels of amoxicillin.

Concomitant use of AMOXIL and oral anticoagulants may increase the prolongation of prothrombin time.

Coadministration with allopurinol increases the risk of rash.

AMOXIL may reduce the efficacy of oral contraceptives.

STORAGE

Store at or below 25°C

OTIBRU

Composition of drug :

Active ingredients:1 g of preparation contains 40 mg phenazone and 10 mg lidocaine hydrochloride;

Excipients: sodium thiosulfate, ethanol, glycerol, purified water.

Pharmacological group. Combination drug for use in otology.

Pharmacological properties. Strong analgesic/anti-inflammatory effect. The action of drug (relieving of tympanum pain and reduction of inflammation) starts 5 minutes after the instillation. The pain disappears within 15–30 minutes.

Indications for use. Local symptomatic treatment and analgesia in:

- acute medium otitis;

- otitis as a complication after flu;

- barotraumatic otitis.

Contraindications. Infectious or traumatic injury of the tympanic membrane. Hypersensitivity to lidocaine or other components of the drug.

Precautions.

Before instilling the drug, it is necessary to check integrity of membrane tympani. If tympanic membrane is perforated, instillation of the drug may lead to contact with medium ear structures and therefore may cause adverse effects.

There are no data about contraindications for using the drug in pregnancy or breastfeeding.

The drug does not affect possibility to drive or operate machinery.

Composition

Each capsule contains pancreatin PhEur 300 mg equivalent to:

Lipase 25,000 PhEur units

Amylase 18,000 PhEur units

Protease 1,000 PhEur units

Indications

For the treatment of pancreatic exocrine insufficiency.

Dosage and Administration

Adults (including the elderly) and children: Initially one or two capsules during or immediately after each meal. Dose increases, if required, should be added slowly, with careful monitoring of response and symptomatology. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with acidic fluid or soft food, but without chewing. This could be apple sauce or yoghurt or any fruit juice with a pH less than 5.5, e.g. apple, orange or pineapple juice. If the granules are mixed with fluid or food, it is important that they are taken immediately and the mixture not stored, otherwise dissolution of the enteric coating may result. In order to protect the enteric coating, it is important that the granules are not crushed or chewed. Crushing and chewing of the mini microspheres or mixing with food or fluid with a pH greater than 5.5 can disrupt the protective enteric coating. It is important to ensure

adequate hydration of patients at all times whilst dosing Creon 25000.

Contraindications

Hypersensitivity to pancreatin of porcine origin or to any of the excipients.

Undesirable effects

The incidence of drug-related adverse effects is very low (<1%). Diarrhoea, constipation, gastric discomfort, nausea and skin reactions have been reported occasionally in patients receiving enzyme replacement therapy.

Overdose

Excessive doses of pancreatin may actuate hyperuricosuria and hyperuricaemia.

Storage

Do not store above 25°C. Keep container tightly closed.

Shelf Life

2 years

ORALDENE

COMPOSITION

ORALDENE contains 0.1% w/v hexetidine.

INDICATIONS

ORALDENE is indicated for use in minor mouth infections including thrush, as an aid in the prevention and treatment of gingivitis, and in the management of sore throat and recurrent aphthous ulcers. ORALDENE is also of value in the alleviation of halitosis and pre- and postdental surgery.

DOSAGE AND ADMINISTRATION

Usual dosage in adults and children 6 years and over:

Shake well before use. Rinse the mouth, or gargle with at least 15 ml of undiluted solution, two or three times a day. Do not swallow the solution but spit out after use.

CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE

ORALDENE mouthwash is for external use only; the solution must therefore not be swallowed.

UNDESIRABLE EFFECTS

ORALDENE is generally very well tolerated with a low potential for causing irritation, or sensitisation reactions. Prolonged use of ORALDENE is also well tolerated.

Possible adverse reactions:

Immune System Disorders: Hypersensitivity reactions; Angioedema

Nervous System Disorders: Dysgeusia

Respiratory, Thoracic and Mediastinal Disorders: Cough; Dyspnoea

Gastrointestinal Disorders: Dry mouth; Dysphagia; Nausea; Salivary gland enlargement; Vomiting

General Disorders and Administration Site Conditions: Transient anaesthesia, Application site reactions.

OVERDOSE

Symptoms

Acute alcoholic intoxication is extremely unlikely, however, it is theoretically possible that, if a

massive dose were swallowed by a small child, alcoholic intoxication may occur due to the ethanol content.

No adverse effects have been reported in overdose other than those seen in normal use.

Hexetidine, at the strength present in ORALDENE, is unlikely to be toxic when used as directed.

Ingestion of sufficient quantities of hexetidine in alcoholic solution may lead to signs/symptoms of alcohol intoxication.

Management

Treatment of overdose is symptomatic, but rarely required. In the event of accidental ingestion of the contents of a bottle by a child, a doctor should be consulted immediately. Gastric lavage should be considered within two hours of ingestion and management should relate to treatment of alcoholic intoxication.

ACECLOFENAC

Composition:

Each film-coated tablet contains100 mg of Aceclofenac.

Indication

Ankylosing spondylitis; Rheumatoid arthritis; Osteoarthritis

Dosage and administration

Adult: 100 mg bid, in the morning and in the evening. Should be taken with food. Take w/or immediately after meals.

Contraindications

Hypersensitivity to aceclofenac or other NSAIDs. Active or history of peptic ulcer/haemorrhage,

history of active bleeding or bleeding disorders, history of bleeding or perforation related to previous NSAID therapy, ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, severe heart failure. Moderate to severe renal and severe hepatic impairment. Pregnancy (3rd trimester).

Special Precautions

Patient w/ulcerative colitis, Crohn's disease, bleeding diathesis or haematological abnormalities.

Patient w/or previous history of asthma. Hepatic and mild renal impairment. Pregnancy and lactation.

Patient Counselling: This drug may cause dizziness, vertigo, drowsiness, fatigue, and visual disturbances, if affected, do not drive or operate machinery.

Monitoring Parameters: Monitor for GI bleeding regularly. Closely monitor cardiac, hepatic, and renal function.

Adverse Drug Reactions

GI disorders (e.g. dyspepsia, abdominal pain, nausea, vomiting, diarrhoea, flatulence, constipation), rash, ruber, urticaria, enuresis, headache, dizziness, paraesthaesia, drowsiness; asthma, bronchospasm, dyspnoea, pruritus, purpura, angioedema. MI, stroke, acute coronary syndrome, oedema, cardiac failure; nephritis, nephritic syndrome, renal failure; abnormal liver function, hepatitis, jaundice; visual disturbance, optic neuritis; thrombocytopenia, neutropenia, agranulocytosis, aplastic and haemolytic anaemias.

Potentially Fatal: GI bleeding, ulceration or perforation.

Overdosage

Symptoms: Headache, nausea, vomiting, epigastric pain, GI irritation and bleeding, diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, hypotension, resp depression, fainting, convulsions, renal failure, liver damage.

Management: Symptomatic and supportive treatment. Employ gastric lavage or activated charcoal w/in 1 hr of ingestion. IV diazepam may be used for prolonged convulsions.

Storage

Store at or below 30°C.

POLYGYNAX

Product Polygynax® vaginal capsules

Composition:

Neomycin sulphate 35,000 IU • Polymyxin B sulphate 35,000 IU • Nystatin 100,000 IU

Therapeutic category:

Topical anti-infectious agent (G. genitourinary tract).

Indication:

Topical treatment of vaginal infections.

Contra indications:

Allergy to one of its ingredients or another substance of the same family. Use of latex diaphragms or condoms. Inform your physician or your pharmacist about all medication you are using with Polygynax® at the same time.

Special Warnings:

Polygynax® contains soybean oil. If you are allergic to peanut or soya, do not use this medicinal product. Stop treatment in case of local intolerance or allergic reactions. In case of local allergy, the subsequent use of the same antibiotic or related antibiotics via the oral route may be compromised.

Precautions:

Inform your physician in case of renal failure. Do not exceed the treatment duration recommended by your physician.

Interactions: Do not use with spermicidal products (risk of inactivation) and condoms

Adverse effects:

Possibility of contact allergic eczema or away from the site of application in case of prolonged use.

Report any unwanted and bothersome effects not mentioned in this insert to your physician or pharmacist.

Pregnancy Lactation:

The use of his drug is not recommended during pregnancy. This drug must not be taken while breast-feeding. In general, pregnant women and nursing mothers should always ask their physician or pharmacist for advice before taking any drugs.

Practical advice:

to avoid contaminating the people around you, use your own face cloth and towel

wear cotton underwear

avoid vaginal douches

avoid using tampons during treatment

do not stop treatment during menstrual periods

your physician may also treat your sexual partner in order to avoid reinfection.

Storage Conditions:

Use before the expiry date indicated on the external packaging. Store below 25°C.

DO NOT SWALLOW. KEEP OUT OF THE REACH AND SIGHT OF CHILDREN.

Lagaay International BV

Van Helmontstraat 99

3029 AA Rotterdam,

The Netherlands

Tel: +31 - 10 4123871

SEPTOZYL

Cream with Neomycin

Topical corticoid for use in skin diseases

Composition

Each one gram of cream contains:

5 mg Neomycin sulfate

1 mg 9a-fluoro-16a-methylprednisolon

Septozyl cream is effective for topical use in skin diseases. The first active substance — a synthetic corticoid ester — has an anti-inflammatory and anti-allergic action, and the second component Neomycin sulfate has antibacterial activity. This composition is available in a specially formulated base, which is excellently tolerated by the skin. Septozyl cream is suitable for use in adults and children.

Indications

Eczema of varying type and localization, including infantile eczema. Various forms of dermatitis, sunburn, otitis externa, intertrigo and napkin rash. Various forms of neurodermatitis. Skin diseases especially psoriasis, lichen planus and chronic discoid lupus erythematosus. Itching of the pudenda and anus.

Application and dosage

Septozyl should be applied to the skin in a thin film several times daily. In some cases, one application a day will prove sufficient. After the skin has healed, Septozyl with neomycin should be applied one time daily for a further 1—2 weeks in order to prevent any recurrence of the disease.

Side effects

After a long-term use of Septozyl, and when the preparation is applied to extensive areas of skin, there is a possibility of the following side effects appearing:

1) hyperglycaemia and glycosuria (in patients with a family history of diabetes mellitus);

2) increased potassium excretion, possibly resulting in hypokalaemic alkalosis;

1) hypertrichosis and acne;

2) sodium and water retention, giving rise to oedema and hypertension,

3) a negative nitrogen balance;

4) clinical picture of Cushing’s syndrome;

7) delayed healing of surgical wounds;

8) prolonged treatment may cause adrenocoptical atrophy.

Contraindications

- Pregnancy, particularly during the first three months.

- Severe renal diseases (excluding nephrosis).

- Psychoses, or a tendency to phychosis.

- Active tuberculosis.

- Infectious diseases.

- Tendency to haemorrage (in patients with peptic ulcer).

Drugs should be kept out of the reach of children. Tel. No. of centre for poisoning cases: 7793777.

Packs: Cream in tubes of 15 g.

TOBRADEX® ST (tobramycin / dexamethasone ophthalmic suspension) 0.3%/0.05%

COMPOSITION

TOBRADEX® ST ophthalmic suspension contains 3 mg/ml tobramycin and 0.5 mg/ml dexamethasone.

INDICATIONS

TOBRADEX® ST is a topical antibiotic and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

DOSAGE AND ADMINISTRATION

Instill one drop into the conjunctival sac(s) every 4 to 6 hours. During the initial 24 to 48 hours, dosage may be increased to one drop every 2 hours. Frequency should be decreased gradually as warranted by improvement in clinical signs, but care should be taken not to discontinue therapy prematurely.

CONTRAINDICATIONS

TOBRADEX® ST, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Hypersensitivity to any component of the medication.

WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, intraocular pressure (IOP) should be monitored.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.

ADVERSE REACTIONS

Most common adverse reactions to topical ocular tobramycin are hypersensitivity and localized ocular toxicity, including eye pain, eyelids pruritus, eyelid edema, and conjunctival hyperemia. The reactions due to the steroid component are increases in intraocular pressure with possible development of glaucoma.

MUCOLYTE

COMPOSITION

Tablets

Each tablet contains:

Active ingredient: Bromhexine HCI 8mg

Excipients: Lactose, starch, gelatin, and magnesium stearate.

Syrup

Each teaspoonful (5ml) contains:

Active ingredient: Bromhexine HCI 4mg

Excipients: Glycerol, benzoic acid, tartaric acid, sodium carboxymethyl cellulose, sorbitol, fruit flavour, and purified water.

MUCOLYTE contains bromhexine which is a synthetic derivative of vasicine (the main active principle of the leaves of Adhatoda vasica).

Bromhexine has an excellent mucolytic effect and is mainly used in the treatment of bronchitis and other respiratory disorders, it acts by changing the structure of bronchial secretions thus reducing the viscosity and increasing the volume of sputum.

For full therapeutic effect. MUCOLYTE should be administered for several days until the patient experiences easier coughing and respiration. It is also given without hesitation for longer periods in chronic respiratory disease conditions.

INDICATIONS

MUCOLYTE liquefies the viscous mucus and is indicated in the following conditions:

- Tracheobronchitis

- Bronchitis with emphysema

- Bronchiectasis

- Bronchitis with bronchospasm

- Chronic inflammatory pulmonary conditions

- Pneumoconiosis

DOSAGE

- The doses and duration of treatment depend upon the severity of the condition.

- Adults and children over 10 years: 1-2 tablets 3 times daily or 10-20ml 3 times daily.

- Children: 5ml 3 times daily.

- Infants & babies: 2.5ml 3 times daily or as directed by the physician.

ADVERSE EFFECTS

- Clinically, bromhexine has been established as a safe drug if administered within the recommended doses. However, some side effects such as headache and nausea are experienced with overdosage.

PRESENTATIONS

Tablets: Packs of 20 tablets. (500 or 1000 tablets) in a hospital pack.

Syrup: Bottles of 100ml.

ZYTIGA® (abiraterone acetate)

Tablet 250 mg

INDICATIONS

ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with

• metastatic castration-resistant prostate cancer (CRPC).

• metastatic high-risk castration-sensitive prostate cancer (CSPC).

DOSAGE AND ADMINISTRATION

Metastatic castration-resistant prostate cancer:

• ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally twice daily.

Metastatic castration-sensitive prostate cancer:

• ZYTIGA 1,000 mg orally once daily with prednisone 5 mg orally once daily.

Patients receiving ZYTIGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ZYTIGA must be taken on an empty stomach with water at least 1 hour before or 2 hours after a meal. Do not crush or chew tablets.

Dose Modification:

• For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the ZYTIGA

starting dose to 250 mg once daily.

• For patients who develop hepatotoxicity during treatment, hold ZYTIGA until recovery. Retreatment may be initiated at a reduced dose. ZYTIGA should be discontinued if patients develop severe hepatotoxicity.

CONTRAINDICATIONS

Pregnancy.

ADVERSE REACTIONS

The most common adverse reactions (≥10%) are fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot fush, diarrhea, vomiting, upper respiratory infection, cough, and headache.

The most common laboratory abnormalities (>20%) are anemia, elevated alkaline phosphatase, hypertriglyceridemia, lymphopenia, hypercholesterolemia, hyperglycemia, and hypokalemia.

WARNINGS AND PRECAUTIONS

Mineralocorticoid excess: Closely monitor patients with cardiovascular disease. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and symptoms of fluid retention at least monthly.

• Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency.

Increased dosage of corticosteroids may be indicated before, during and after stressful situations.

• Hepatotoxicity: Can be severe and fatal. Monitor liver function and modify, interrupt, or discontinue

ZYTIGA dosing as recommended.

STORAGE

Store at 20°C to 25°C.

Keep out of reach of children.

 

COMPOSITION

a) Each enteric coated tablet contains Diclofenac Sodium 25 mg.

b) Each enteric coated tablet contains Diclofenac Sodium 50 mg.

c) Each enteric coated tablet contains Diclofenac Sodium 100 mg.

d) DIC INJECTION Each ml of injection contains Diclofenac Sodium 25 mg.

DESCRIPTION

DIC (Diclofenac) is a potent non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. It also has some uricosuric effect. Diclofenac inhibits cyclo-oxygenase activity with a reduction in the tissue production of prostaglandins such as PgF2 and PgE2.The anti-inflammatory effect, measured in the adjuvant induced arthritis model is greater than that of aspirin and similar to indomethacin.

INDICATIONS

- Rheumatoid arthritis.

- Osteoarthritis.

- Low back pain and other acute musculoskeletal disorders such as tendonitis, tenosynovitis, bursitis, sprains, strains and dislocations.

- Ankylosing spondylitis.

- Acute gout.

- Control of pain and inflammation in orthopaedic, dental other minor surgery.

- Juvenile chronic arthritis.

- Postoperative pain.

- Pain of renal colic.

CONTRAINDICATIONS

Active or suspected peptic ulcer or gastrointestinal bleeding.

Previous sensitivity to diclofenac sodium.

Asthmatic patients in whom attacs of asthma, urticarial or acute rhinitis are precipitated by aspirin or other NSAID`s possessing prostaglandin synthetase inhibiting activity.

DOSAGE AND ADMINISTRATION

a) Oral. For symptomatic relief of rheumatoid arthritis, the usual daily dosage is 150 to 200 mg given in two to four divided doses.

For osteoarthritis, 100 to 150 mg is given daily in two or three divided doses.

For ankylosing spondylitis, 100 to 125 mg is given daily in four or five divided doses.

b) Parenteral. 75 mg i. m. 1-2 times daily by deep intragluteal injection for 2-3 days.

PRECAUTIONS

DIC (Diclofenac) may be used cautiously in patients with history of dyspepsia, or other g.i. disorders, blood coagulation disorders, severe hepatic or renal disease. Perform blood counts during long-term therapy. Sately in pregnancy lactation and children has not been established.

PRESENTATION

DIC tablets of 25 mg, 50 mg and 100 mg are available in pack of 10’s and in bulk pack of 1000’s.

DIC injection is available in clear glass ampoules of 3 ml.

 

 

DAFLON

Contents
Micronized, purified flavonoid fraction (diosmin 450 mg, hesperidin 50 mg).


Description

Each film-coated tablet contains micronized purified flavonoid fraction 500 mg (diosmin 450 mg and flavonoids expressed as hesperidin 50 mg).

Mechanism of Action

Daflon exerts an action on the vasculary return system. At the venous level, it reduces venous distensibility and reduces venous stasis. At the microcirculatory level, it normalises capillary permeability and reinforces capillary resistance.

Indications

Treatment of symptoms related to venolymphatic insufficiency (heavy legs, pain). Treatment of functional symptoms related to acute hemorrhoidal attack.


Поделиться:



Последнее изменение этой страницы: 2019-03-20; Просмотров: 463; Нарушение авторского права страницы


lektsia.com 2007 - 2024 год. Все материалы представленные на сайте исключительно с целью ознакомления читателями и не преследуют коммерческих целей или нарушение авторских прав! (0.314 с.)
Главная | Случайная страница | Обратная связь